Global Medical Cures™ | Novel New Drugs- 2013 Summary CDER FDA

Global Medical Cures™ | Novel New Drugs- 2013 Summary CDER FDA

• 1.
  APPROVED DRUGS 2013 Adempas Anoro Ellipta Aptiom BreoEllipta Brintellix Dotarem Duavee Gazyva Gilotrif Imbruvica Invokana Kadcyla Kynamro Luzu Lymphoseek Mekinist Nesina Olysio Opsumit Osphena Pomalyst Sovaldi Tafinlar Tecfidera Tivicay Vizamyl Xofigo s
• 3.
  2 Ten Year HistoricComparison CDER’s 2013 Novel New Drugs 27 novel new drugs in CY 2013: In Calendar Year 2013, FDA’s Center for Drug Evaluation and Research (CDER) approved 27 novel new medicines, known as new molecular entities (NMEs). For the purposes of this report, the term NME applies to novel new drugs approved under both New Drug Applications (NDAs) and Biologics License Applications (BLAs). The chart below lists CDER’s 2013 NMEs. In 2013 CDER approved 27 NMEs are often innovative new products that serve previously unmet medical needs or otherwise significantly help to advance patient care and public health. However, in some cases, while categorized as novel for technical and/or administrative purposes, a particular NME may not necessarily offer unique clinical advantages over existing therapies. This report summarizes all NMEs of 2013, with an emphasis on those that offer new and innovative treatments to patients in need. The dark blue bars in the chart to the right indicate the number of NMEs approved by CDER in each year of the past decade. CDER approved 27 NMEs in 2013, which is similar to average totals of other years from this time period. For instance from 2004 through 2012, CDER has averaged about 26 NME approvals per year. In 2012, CDER approved 39 NMEs, but this was an unusually high number compared to any other total in more than a decade. NMEs Applications for new approvals remain steady The number of applications CDER has been receiving for NMEs has not been consistently and significantly increasing. The light blue portion of the graph to the right indicates the number of new NDA and BLA applications for NMEs CDER has filed over the last ten years. From 2004 through 2012, CDER filed an average of about 34 applications for NMEs per year. Although all applications submitted in 2013 had not yet been accepted for filing as of 12/31/13, CDER projects about 36 for 2013, which is consistent with previous years in this decade. With a relatively steady number of applications coming in over time, it is noteworthy that FDA cannot expect a continuing upward trend for NME approvals until a sustained increase in the number of applications for NMEs submitted for approval is also demonstrated. CDER’s NMEs of CY 2013: see pages 14 & 15 for what these drugs are used for. Adempas Anoro Ellipta Aptiom Breo Ellipta Brintellix Dotarem Duavee Gazyva Gilotrif Imbruvica Invokana Kadcyla Kynamro Luzu Lymphoseek Mekinist Nesina Olysio Opsumit Osphena Pomalyst Sovaldi Tafinlar Tecfidera Tivicay Vizamyl Xofigo For more details about the individual NMEs, see pages 14 & 15.
• 4.
  Ten Year HistoricComparison From 2004 through 2012, CDER has averaged 27 NMEs approved in CY 2013 is similar to the average totals approved in the past decade 26 NME approvals per year 45 41 35 38 36 35 32 41 39 36 34 30 36 * 30 26 25 20 20 24 22 26 27 23 21 18 15 2013 2012 2011 2010 2009 2008 2007 0 2006 5 2005 10 2004 # NME Approvals and Applications Filed 40 Calendar Year NME Approvals NME Applications Filed * - The filed numbers include those filed in CY 2013 plus those currently pending filing (i.e., within their 60 day filing period) in CY 2013. - Receipts that received a “Refuse to File” (RTF) or “Withdrawn before filing” (WF) identifier are excluded. - Multiple submissions (multiple or split originals) pertaining to a single new molecular/biologic entity are only counted once. - There is a BLA included that does not currently have a review schedule but is known to contain a new active ingredient. - The filed number is not indicative of workload in the PDUFA V Program. 3
• 5.
  4 Impact on PublicHealth Impact Impact on Public Health Many of the 27 NMEs approved by CDER in CY 2013 are notable for their potential positive impact and unique contributions to quality care and public health. First-in-Class Adempas Imbruvica Invokana Kadcyla Kynamro Mekinist Sovaldi Tecfidera Xofigo One-third (33%) of the NMEs approved in CY 2013 (9 of 27) were identified by FDA as First-in-Class, meaning drugs which, for example, use a new and unique mechanism of action for treating a medical condition. First-in-Class is one indicator of the innovative nature of a drug and a 33% First-in-Class approval rate suggests that the group of CY 2013 NMEs is a field of innovative new products. Noteworthy First-in-Class products include: Invokana - for type 2 diabetes glycemic control Kadcyla - for HER2-positive late-stage (metastatic) breast Sovaldi - an interferon-free oral treatment option for some cancer patients with chronic hepatitis C for metastatic melanoma Mekinist - 33 % First-in-Class Drugs For more details about the individual NMEs, see pages 14 & 15.
• 6.
  Impact on PublicHealth One-third (33%) of the NMEs approved in CY 2013 (9 of 27) were approved to treat rare or “orphan” diseases that affect 200,000 or fewer Americans. This is significant because patients with rare diseases often have few or no drug treatment options. Orphan Drugs Adempas Gazyva Noteworthy examples of rare diseases that now have new or additional effective treatment options include: Imbruvica Mantle cell lymphoma - Imbruvica Chronic lymphocytic leukemia - Gazyva Homozygous familial hypercholesterolemia - Kynamro Pulmonary arterial hypertension - Adempas and Opsumit Opsumit 33 % Orphan Drugs Gilotrif Kynamro Mekinist Pomalyst Tafinlar 5
• 7.
  6 Impact on PublicHealth Notable NMEs of 2013: Another strong year for quality In addition to the nine noteworthy examples of innovative Firstin-Class and “orphan” new products mentioned on pages 4 and 5, the 27 NMEs approved in CY 2013 also include Gilotrif to treat late stage (metastatic) non-small cell lung cancer, Tafinlar to treat patients with certain forms of melanoma, Tecfidera to Sovaldi treat adults with relapsing forms of multiple sclerosis, and Olysio for patients with chronic hepatitis C. Treatment for patients with chronic hepatitis C. Olysio Treatment for patients with chronic hepatitis C. Imbruvica Gilotrif Treatment for mantle cell lymphoma. Treatment for late stage (metastatic) non-small cell lung cancer. For more details about the individual NMEs, see pages 14 & 15. Invokana Treatment for type 2 diabetes glycemic control.
• 8.
  Impact on PublicHealth Mekinist Treament for melanoma. Adempas Treatment for pulmonary arterial hypertension. Tafinlar Treament for melanoma. Gazyva Treatment for chronic lymphocytic leukemia. Opsumit Treatment for pulmonary arterial hypertension. Kadcyla Treatment for HER2-positive late-stage (metastatic) breast cancer. Kynamro Tecfidera Treatment for patients with homozygous familial hypercholesterolemia. Treatment for adults with relapsing forms of multiple sclerosis. 7
• 9.
  8 Innovative Methods forExpediting NMEs to Market Innovation Innovative methods for expediting NMEs to market Many of the 27 NMEs of CY 2013 approved by CDER are notable for the regulatory methods CDER used to expedite the development and approval process. From time of submission to their approval dates, some drugs were under review for only several months prior to approval. Particularly noteworthy examples of drugs approved rapidly are Gazyva approved in 6.3 months, Imbruvica approved in 4.5 months, and Xofigo approved in 5.0 months, all approved earlier than their goal dates for regulatory action. There are four FDA expedited review and approval pathways: Fast Track, Breakthrough, Priority Review, and Accelerated Approval. Fast Track Gilotrif Pomalyst Imbruvica Sovaldi Kadcyla Tafinlar Mekinist Tivicay Olysio Xofigo Ten of the 27 NMEs approved in 2013 (37%) were designated by CDER as Fast Track, meaning drugs with the potential to address unmet medical needs. Fast Track speeds new drug development and review, for instance, by increasing the level of communication FDA allocates to developers and by enabling developers to use a “rolling review” process such that CDER can review portions of an application ahead of the submission of the full application. Three of the 27 NMEs approved in 2013 (11%) were designated by CDER as Breakthrough therapies, meaning drugs with preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. A breakthrough therapy designation conveys all of the fast track program features, as well as more intensive FDA guidance on an efficient drug development program. Breakthrough status is designed to help shorten the development time of a promising new therapy. This is a new designation that went into effect after July 9, 2012. 2013 is the first year any new drug was approved with the breakthrough designation. Breakthrough Gazyva Imbruvica Sovaldi Priority Review Adempas Kadcyla Dotarem Olysio Gazyva Sovaldi Gilotrif Tivicay Imbruvica Ten of the 27 NMEs approved in 2013 (37%) were designated Priority Review, in which CDER determines the drug to potentially provide a significant advance in medical care and sets a target to review the drug within six months instead of the standard 10 months. Xofigo Two of the 27 NMEs approved in 2013 (7%) were approved under FDA’s Accelerated Approval program, which allows early approval of a drug for serious or life-threatening illness that offers a benefit over current treatments. This approval is based on a “surrogate endpoint” (e.g., a laboratory measure) or other clinical measure that FDA considers reasonably likely to predict clinical benefit. After this approval, the drug must undergo additional testing to confirm that benefit; this speeds the availability of the drug. For more details about the individual NMEs, see pages 14 & 15. Accelerated Approval Imbruvica Pomalyst
• 10.
  Innovative Methods forExpediting NMEs to Market Combined expedited approval methods Drugs are not limited to one expedited development and approval method. In many cases, CDER uses one or more of these tools to speed development and approval. Almost half (48%) of the 27 NMEs approved in CY 2013 (13 of 27) were designated in one or more categories of Fast Track, Breakthrough, Priority Review, and/or Accelerated Approval. Each of these designations helps expedite the speed of the development and/or approval process and is designed to help bring important medications to the market as quickly as possible. 48 % Combined Adempas Imbruvica Olysio Tafinlar Dotarem Kadcyla Pomalyst Tivicay Gazyva Mekinist Sovaldi Xofigo Gilotrif Fast Track 37 % Breakthrough 11 % Priority Review 37 % Accelerated Approval 7 % 9
• 11.
  10 Approval Predictability Predictability Under thePrescription Drug User Fee Act (PDUFA), sponsors are assessed user fees that provide FDA with the additional resources needed to meet performance goals. Throughout the year, CDER was able to meet or exceed PDUFA goal dates for application review, agreed to with the pharmaceutical industry and approved by Congress. In CY 2013, CDER met its PDUFA goal dates for 100% of the NMEs approved in CY 2013. PDUFA Goal Dates Met Adempas Anoro Ellipta Aptiom Breo Ellipta Brintellix Dotarem Duavee Gazyva Gilotrif Imbruvica Invokana Kadcyla Kynamro Lymphoseek Mekinist Nesina Olysio Opsumit Osphena Pomalyst Sovaldi Tafinlar Tecfidera Tivicay Vizamyl Xofigo Luzu % 100 Percentage of PDUFA goal dates met in CY 2013 for each NME. For more details about the individual NMEs, see pages 14 & 15.
• 12.
  Approval Access Access CDER approvedmost drugs (24 of 27) on the “first cycle” of review (89%), meaning without requests for additional information that would delay approval and lead to another cycle of review. 89 % First Cycle Approval First Cycle Approval Adempas Gazyva Luzu Sovaldi Anoro Ellipta Gilotrif Mekinist Tafinlar Breo Ellipta Imbruvica Olysio Tecfidera Brintellix Invokana Opsumit Tivicay Dotarem Kadcyla Osphena Vizamyl Duavee Kynamro Pomalyst Xofigo Ten of the 24 First Cycle Approvals listed above are also designated as Priority Review drugs. This is particularly important because Priority Review drugs have the potential to serve as significant medical advances in health care. 74 % First Approved in U.S. Approval in U.S. before Other Countries Anoro Ellipta Imbruvica Mekinist Tafinlar Breo Ellipta Invokana Opsumit Tecfidera Brintellix Kadcyla Osphena Tivicay Gazyva Kynamro Pomalyst Vizamyl Gilotrif Lymphoseek Sovaldi Xofigo Comparing approval to other countries offers another measure of approval efficiency. Although regulatory processes differ widely between FDA and those of regulatory agencies in other countries, almost three-quarters (74%) of the NMEs approved in CY 2013 (20 of 27) were approved first in the U.S. before any other country. 11
• 13.
  12 Summary Overview This document representsa broad overview of CDER approvals of new molecular entities (NMEs) for calendar year 2013. A continuing upward trend for the annual number of CDER’s NME approvals necessarily relies upon a corresponding upward trend in the number of applications submitted for approval. Over the past decade, submissions for NMEs by the pharmaceutical and biotechnology industry have not been increasing. In other words, over time, CDER can only approve a number of NMEs proportional to the number of applications for NMEs it receives. More important than the quantity of new drugs approved in 2013 is the quality of the new drugs the pharmaceutical industry has developed and the important new roles these drugs are serving to advance medical care. Also noteworthy is the efficiency with which most of these drugs were reviewed and approved. CDER used a variety of “expedited development and approval” regulatory tools to speed these drugs to market. In all cases, while striving for efficiency of review and approval of applications for new drugs, CDER does not compromise its standards for demonstration of effectiveness and safety in the process. More important than the quantity of new drugs approved by CDER in CY 2013 is the quality of the new drugs and the important new roles they are serving to advance medical care. For more details about the individual NMEs, see pages 14 & 15.
• 14.
  Adempas Anoro Ellipta Aptiom Breo Ellipta Fas tT rac k Bre akt hro ugh Prio rity Rev iew Acc eler ate dA ppr Met ova l PDU FA Goa lDa Firs tes tC ycle Firs tA ppr ove d in U. S . Orp han Firs t- in-C lass Summary 13 Drug Designation Summary First-in-Class Drugs with a new and unique mechanism for treating a medical condition. Brintellix Orphan Drugs Dotarem Drugs approved for small populations of patients with rare diseases. Duavee Gazyva Gilotrif Imbruvica Invokana Kadcyla Kynamro Luzu Lymphoseek Mekinist Nesina Olysio Opsumit Osphena Pomalyst Sovaldi Tafinlar Tecfidera Tivicay Vizamyl Xofigo Fast Track Drugs that can treat unmet medical needs. Breakthrough Drugs with preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. Priority Review A drug is given a priority review if there is potential to provide a significant advance in medical care. Accelerated Approval Early approval based on markers that predict a reasonable benefit, with more testing to confirm clinical benefit after approval. PDUFA Goal Dates Drugs that met the Prescription Drug User Fee Act goal dates for the year. First Cycle Drugs that were approved without request for additional information that would delay approval and lead to another cycle of review. First Approved in U.S. Drugs that were approved first in the U.S. before any other country worldwide.
• 15.
  14 The NMEs of2013 Drugs listed by date of approval. Drug Name Active Ingredient Date What it used for Nesina alogliptin 1/25/2013 To improve blood sugar control in adults with type 2 diabetes. Kynamro mipomersen sodium 1/29/2013 To treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). Pomalyst pomalidomide 2/8/2013 To treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Kadcyla ado-trastuzumab emtansine 2/22/2013 For patients with HER2-positive, late-stage (metastatic) breast cancer. 2/26/2013 To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause. Osphena ospemifene Lymphoseek technetium Tc 99m tilmanocept 3/13/2013 A radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumordraining lymph nodes. Dotarem gadoterate meglumine 3/20/2013 For use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older. Tecfidera dimethyl fumarate 3/27/2013 To treat adults with relapsing forms of multiple sclerosis (MS). Invokana canagliflozin 3/29/2013 Used with diet and exercise to improve glycemic control in adults with type 2 diabetes. Breo Ellipta fluticasone furoate and vilanterol inhalation powder 5/10/2013 For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/ or emphysema. Xofigo radium Ra 223 dichloride 5/15/2013 To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. Tafinlar dabrafenib 5/29/2013 To treat patients with melanoma whose tumors express the BRAF V600E gene mutation. Mekinist trametinib 5/29/2013 To treat patients whose tumors express the BRAF V600E or V600K gene mutations. 7/12/2013 For patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Gilotrif afatinib To view this full summary online please visit the CDER web page spotlight on Drug Innovation...
• 16.
  15 Drug Name Active Ingredient Date Whatit used for Tivicay dolutegravir 8/12/2013 To treat HIV-1 infection. Brintellix vortioxetine 9/30/2013 To treat adults with major depressive disorder. Duavee conjugated estrogens/ bazedoxifene 10/3/2013 To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause. Adempas riociguat 10/8/2013 To treat adults with two forms of pulmonary hypertension. Opsumit macitentan 10/18/2013 To treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation. Vizamyl flutemetamol F 18 injection 10/25/2013 A radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer’s disease (AD) and dementia. Gazyva obinutuzumab 11/1/2013 For use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL). Aptiom eslicarbazepine acetate 11/8/2013 As an add-on medication to treat seizures associated with epilepsy. Imbruvica ibrutinib 11/13/2013 To treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. Luzu luliconozole 11/14/2013 For the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older. Olysio simeprevir 11/22/2013 To treat chronic hepatitis C virus (HCV) infection. Sovaldi sofosbuvir 12/6/2013 To treat chronic hepatitis C virus (HCV) infection. Anoro Ellipta umeclidinium and vilanterol inhalation powder 12/18/2013 For the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm